Carl Dambkowski Sells 1,590 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 1,590 shares of the firm’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.48, for a total value of $48,463.20. Following the completion of the transaction, the insider now owns 251,033 shares of the company’s stock, valued at approximately $7,651,485.84. This represents a 0.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The shares were sold at an average price of $40.69, for a total value of $143,228.80.
• On Thursday, January 2nd, Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock. The shares were sold at an average price of $46.94, for a total value of $191,749.90.
• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.76, for a total value of $221,370.40.

Apogee Therapeutics Trading Up 2.0 %

Shares of NASDAQ:APGE opened at $36.14 on Monday. The stock’s 50-day moving average price is $38.92 and its two-hundred day moving average price is $46.90. Apogee Therapeutics, Inc. has a 12-month low of $29.10 and a 12-month high of $72.29. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -14.93 and a beta of 2.46.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). As a group, research analysts forecast that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on APGE. Wedbush reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research note on Monday, March 3rd. Canaccord Genuity Group began coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Canaccord Genuity Group began coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $91.60.

Institutional Trading of Apogee Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its stake in shares of Apogee Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company’s stock valued at $432,000 after purchasing an additional 892 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Apogee Therapeutics by 4.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,835 shares of the company’s stock valued at $1,078,000 after purchasing an additional 931 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Apogee Therapeutics in the 4th quarter valued at about $43,000. Arizona State Retirement System lifted its stake in shares of Apogee Therapeutics by 17.3% in the 4th quarter. Arizona State Retirement System now owns 6,517 shares of the company’s stock valued at $295,000 after purchasing an additional 960 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its stake in shares of Apogee Therapeutics by 8.9% in the 4th quarter. New York State Common Retirement Fund now owns 12,187 shares of the company’s stock valued at $552,000 after purchasing an additional 1,000 shares in the last quarter. 79.04% of the stock is owned by institutional investors and hedge funds.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.